Abbott Laboratories (NYSE:ABT) Vs. Sigilon Therapeutics (NASDAQ:SGTX) Financial Analysis
Abbott Laboratories (NYSE:ABT) Vs. Sigilon Therapeutics (NASDAQ:SGTX) Financial Analysis
Abbott Laboratories (NYSE:ABT – Get Rating) and Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
雅培实验室（纽约证券交易所代码：ABT — 获取评级）和Sigilon Therapeutics（纳斯达克股票代码：SGTX — 获取评级）都是医疗公司，但哪只是优势股？我们将根据两家企业的股息、估值、机构所有权、分析师建议、盈利能力、风险和收益进行比较。
Insider and Institutional Ownership
内部所有权和机构所有权
72.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 52.2% of Sigilon Therapeutics shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by insiders. Comparatively, 4.2% of Sigilon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
雅培实验室72.9％的股票由机构投资者持有。相比之下，Sigilon Therapeutics有52.2％的股票由机构投资者持有。雅培实验室0.5％的股票由内部人士持有。相比之下，Sigilon Therapeutics有4.2％的股票由内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为，从长远来看，股票的表现将超过市场。
Profitability
盈利能力
This table compares Abbott Laboratories and Sigilon Therapeutics' net margins, return on equity and return on assets.
该表比较了雅培实验室和Sigilon Therapeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Abbott Laboratories | 15.88% | 26.09% | 12.82% |
| Sigilon Therapeutics | -336.53% | -87.15% | -41.94% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 雅培实验室 | 15.88% | 26.09% | 12.82% |
| 西吉隆疗法 | -336.53% | -87.15% | -41.94% |
Analyst Recommendations
分析师建议
This is a breakdown of current recommendations and price targets for Abbott Laboratories and Sigilon Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的雅培实验室和Sigilon Therapeutics当前的建议和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abbott Laboratories | 1 | 3 | 10 | 0 | 2.64 |
| Sigilon Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 卖出评级 | 持有评级 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 雅培实验室 | 1 | 3 | 10 | 0 | 2.64 |
| 西吉隆疗法 | 0 | 0 | 1 | 0 | 3.00 |
Abbott Laboratories currently has a consensus price target of $124.67, suggesting a potential upside of 27.38%. Sigilon Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 512.18%. Given Sigilon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sigilon Therapeutics is more favorable than Abbott Laboratories.
雅培实验室目前的共识目标价为124.67美元，这表明潜在的上涨空间为27.38％。Sigilon Therapeutics的共识目标价为6.00美元，这表明潜在的上涨空间为512.18％。鉴于Sigilon Therapeutics更高的共识评级和更高的可能上行空间，分析师显然认为Sigilon Therapeutics比雅培实验室更有利。
Earnings and Valuation
收益和估值
This table compares Abbott Laboratories and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.
该表比较了雅培实验室和Sigilon Therapeutics的营收收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abbott Laboratories | $43.65 billion | 3.90 | $6.93 billion | $3.91 | 25.03 |
| Sigilon Therapeutics | $12.94 million | 2.46 | -$77.31 million | ($1.35) | -0.73 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 雅培实验室 | 436.5 亿美元 | 3.90 | 69.3 亿美元 | 3.91 | 25.03 |
| 西吉隆疗法 | 1,294 万美元 | 2.46 | -7,731 万美元 | (1.35 美元) | -0.73 |
Abbott Laboratories has higher revenue and earnings than Sigilon Therapeutics. Sigilon Therapeutics is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.
雅培实验室的收入和收益高于Sigilon Therapeutics。Sigilon Therapeutics的市盈率低于雅培实验室，这表明它目前是这两只股票中更实惠的一只。
Volatility & Risk
波动性与风险
Abbott Laboratories has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Sigilon Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
雅培实验室的beta值为0.68，这表明其股价的波动性比标准普尔500指数低32％。相比之下，Sigilon Therapeutics的beta值为0.86，这表明其股价的波动性比标准普尔500指数低14％。
Summary
摘要
Abbott Laboratories beats Sigilon Therapeutics on 10 of the 14 factors compared between the two stocks.
比较两只股票的14个因素中，雅培实验室在10个因素上击败了Sigilon Therapeutics。
About Abbott Laboratories
关于雅培实验室
(Get Rating)
（获取评级）
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1900 and is headquartered in Abbott Park, IL.
Abbott Laboratories 从事广泛而多样化的医疗保健产品的发现、开发、制造和销售。它通过以下业务部门运营：成熟药品、诊断产品、营养产品和医疗器械。成熟药品板块是指一系列品牌仿制药产品的国际销售。诊断产品部门为血库、医院、商业实验室和替代护理测试场所销售诊断系统和测试。营养产品部门可满足成人和儿科营养产品的全球销售。医疗器械领域包括用于治疗心血管疾病的电生理学、心力衰竭、血管和结构性心脏设备，为糖尿病患者提供糖尿病护理产品，以及用于管理慢性疼痛和运动障碍的神经调节设备。该公司由华莱士·卡尔文·阿伯特于1900年创立，总部位于伊利诺伊州雅培公园。
About Sigilon Therapeutics
Sigilon Therapeutics
(Get Rating)
（获取评级）
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics, Inc. 是一家临床阶段的生物技术公司，为慢性病患者开发功能性疗法。其主要候选产品是 SIG-001，它正处于 I/II 期临床试验，旨在预防中度至重度 A 型血友病患者出血发作。该公司还在开发 SIG-005 来治疗 1 型粘多糖增多症的非神经系统表现；SIG-007 用于持续和长时间释放功能酶，其水平足以产生临床益处和缓解 Fabry 病下游方面的进展；以及用于取代胰岛细胞治疗 1 型糖尿病的 SIG-002。Sigilon Therapeutics, Inc. 与礼来公司签订了研究合作和许可协议，用于开发和商业化治疗1型糖尿病的slTx候选产品。该公司前身为Sigilon, Inc.，并于2017年6月更名为Sigilon Therapeutics, Inc.Sigilon Therapeutics, Inc. 成立于2015年，总部位于马萨诸塞州剑桥。
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
接收雅培实验室每日的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收雅培实验室及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。